IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma
IDEXX Laboratories (NASDAQ: IDXX) has announced the launch of IDEXX Cancer Dx™, a groundbreaking diagnostic panel for early detection of lymphoma in dogs. The affordable blood test, priced as low as $15, can be integrated into annual wellness screenings and provides results within 2-3 days.
The test targets the significant market of 20 million dogs at higher risk for cancer in North America, addressing a critical need as 1 in 4 dogs in the U.S. are expected to receive a cancer diagnosis in their lifetime. Lymphoma specifically accounts for nearly 25% of new canine cancer diagnoses.
The panel features high accuracy, simple workflow integration, and includes access to IDEXX Medical Consultants. The test can detect lymphoma before clinical signs appear and will provide B-cell and T-cell phenotype classification for positive results at no additional cost. The service will be available in the U.S. and Canada in late March 2025, with plans to expand the panel over the next three years to cover the majority of canine cancer cases.
IDEXX Laboratories (NASDAQ: IDXX) ha annunciato il lancio di IDEXX Cancer Dx™, un pannello diagnostico innovativo per la rilevazione precoce del linfoma nei cani. Il test del sangue, accessibile a partire da 15 dollari, può essere integrato nei controlli di benessere annuali e fornisce risultati entro 2-3 giorni.
Il test si rivolge a un mercato significativo di 20 milioni di cani a maggior rischio di cancro in Nord America, rispondendo a una necessità critica poiché 1 cane su 4 negli Stati Uniti è previsto ricevere una diagnosi di cancro nel corso della vita. Il linfoma rappresenta in particolare quasi il 25% delle nuove diagnosi di cancro nei cani.
Il pannello offre alta accuratezza, integrazione semplice nel flusso di lavoro e include l'accesso ai consulenti medici di IDEXX. Il test può rilevare il linfoma prima che compaiano segni clinici e fornirà la classificazione del fenotipo delle cellule B e T per i risultati positivi senza costi aggiuntivi. Il servizio sarà disponibile negli Stati Uniti e in Canada a partire da fine marzo 2025, con piani per espandere il pannello nei prossimi tre anni per coprire la maggior parte dei casi di cancro nei cani.
IDEXX Laboratories (NASDAQ: IDXX) ha anunciado el lanzamiento de IDEXX Cancer Dx™, un panel de diagnóstico innovador para la detección temprana de linfoma en perros. La prueba de sangre, con un precio tan bajo como 15 dólares, puede integrarse en los chequeos de bienestar anuales y proporciona resultados en un plazo de 2 a 3 días.
La prueba está dirigida a un mercado significativo de 20 millones de perros en mayor riesgo de cáncer en América del Norte, abordando una necesidad crítica ya que se espera que 1 de cada 4 perros en los EE. UU. reciba un diagnóstico de cáncer en su vida. El linfoma representa casi el 25% de los nuevos diagnósticos de cáncer canino.
El panel ofrece alta precisión, integración simple en el flujo de trabajo e incluye acceso a consultores médicos de IDEXX. La prueba puede detectar linfoma antes de que aparezcan los signos clínicos y proporcionará clasificación de fenotipo de células B y T para resultados positivos sin costo adicional. El servicio estará disponible en EE. UU. y Canadá a finales de marzo de 2025, con planes de expandir el panel durante los próximos tres años para cubrir la mayoría de los casos de cáncer canino.
IDEXX Laboratories (NASDAQ: IDXX)는 개의 림프종 조기 발견을 위한 혁신적인 진단 패널인 IDEXX Cancer Dx™의 출시를 발표했습니다. 가격이 15달러 이하인 이 저렴한 혈액 검사는 연간 건강 검진에 통합될 수 있으며 2-3일 이내에 결과를 제공합니다.
이 검사는 북미에서 암에 대한 높은 위험을 가진 2000만 마리의 개를 목표로 하고 있으며, 미국에서는 4마리 중 1마리가 평생 동안 암 진단을 받을 것으로 예상되는 중요한 필요성을 해결하고 있습니다. 림프종은 새로운 개암 진단의 거의 25%를 차지합니다.
이 패널은 높은 정확성과 간단한 작업 흐름 통합을 제공하며 IDEXX 의료 컨설턴트에 대한 접근이 포함되어 있습니다. 이 검사는 임상 증상이 나타나기 전에 림프종을 감지할 수 있으며, 양성 결과에 대한 B세포 및 T세포 표현형 분류를 추가 비용 없이 제공합니다. 이 서비스는 2025년 3월 말에 미국과 캐나다에서 제공될 예정이며, 향후 3년 동안 개암 사례의 대부분을 포함하도록 패널을 확장할 계획입니다.
IDEXX Laboratories (NASDAQ: IDXX) a annoncé le lancement de IDEXX Cancer Dx™, un panel de diagnostic révolutionnaire pour la détection précoce des lymphomes chez les chiens. Ce test sanguin abordable, à partir de 15 dollars, peut être intégré aux bilans de santé annuels et fournit des résultats en 2 à 3 jours.
Le test cible un marché important de 20 millions de chiens à risque accru de cancer en Amérique du Nord, répondant à un besoin critique dans un contexte où 1 chien sur 4 aux États-Unis devrait recevoir un diagnostic de cancer au cours de sa vie. Le lymphome représente à lui seul près de 25 % des nouveaux diagnostics de cancer canin.
Le panel offre une grande précision, une intégration facile dans le flux de travail et inclut un accès aux consultants médicaux d'IDEXX. Le test peut détecter le lymphome avant l'apparition des signes cliniques et fournira une classification des phénotypes des cellules B et T pour les résultats positifs, sans frais supplémentaires. Le service sera disponible aux États-Unis et au Canada fin mars 2025, avec des projets d'élargir le panel au cours des trois prochaines années pour couvrir la plupart des cas de cancer chez les chiens.
IDEXX Laboratories (NASDAQ: IDXX) hat die Einführung von IDEXX Cancer Dx™ bekannt gegeben, einem bahnbrechenden Diagnosetool zur Früherkennung von Lymphomen bei Hunden. Der erschwingliche Bluttest, der bereits ab 15 Dollar erhältlich ist, kann in die jährlichen Gesundheitsuntersuchungen integriert werden und liefert Ergebnisse innerhalb von 2-3 Tagen.
Der Test richtet sich an den großen Markt von 20 Millionen Hunden, die in Nordamerika ein höheres Krebsrisiko haben, und erfüllt einen kritischen Bedarf, da in den USA jeder vierte Hund im Laufe seines Lebens mit einer Krebsdiagnose gerechnet werden muss. Lymphome machen dabei fast 25 % der neuen Diagnosen von Krebserkrankungen bei Hunden aus.
Das Panel bietet hohe Genauigkeit, einfache Integration in den Arbeitsablauf und beinhaltet den Zugang zu IDEXX Medizinberatern. Der Test kann Lymphome erkennen, bevor klinische Symptome auftreten, und es werden kostenfrei B-Zell- und T-Zell-Phänotyp-Klassifizierungen für positive Ergebnisse zur Verfügung gestellt. Der Dienst wird Ende März 2025 in den USA und Kanada verfügbar sein, mit Plänen, das Panel in den nächsten drei Jahren zu erweitern, um die meisten Fälle von Krebs bei Hunden abzudecken.
- Introduction of innovative early cancer detection test with affordable pricing ($15)
- Large addressable market of 20 million at-risk dogs in North America
- Planned expansion to cover majority of canine cancer types over next 3 years
- High market demand indicated by 73% of pet owners interested in cancer screening
- Additional revenue stream through integration with existing diagnostic wellness panels
- None.
Insights
The launch of IDEXX Cancer Dx marks a pivotal moment in veterinary diagnostics with significant market implications. The addressable market is substantial - with 20 million high-risk dogs in North America and 25% of dogs developing cancer in their lifetime, the potential annual testing revenue could exceed
The
The B-cell and T-cell phenotype classification included at no additional cost is particularly noteworthy, as it provides critical prognostic information that typically requires additional testing. This feature could accelerate market penetration by offering superior clinical value compared to traditional diagnostic pathways.
The planned three-year expansion to cover additional cancer types suggests a calculated product rollout strategy. By starting with lymphoma, which represents
The integration with IDEXX Preventive Care creates powerful network effects, potentially increasing the stickiness of IDEXX's entire diagnostic ecosystem. This could further solidify their market leadership and create significant barriers to entry for competitors.
Panel expansion planned over the next three years to cover the majority of canine cancer cases, transforming cancer detection and supporting earlier intervention
Cancer remains a leading cause of death in canines, with 1 in 4 dogs in the
"Building on over 40 years of IDEXX's leadership in veterinary research and technology development, IDEXX Cancer Dx is our latest groundbreaking solution to deliver unmatched diagnostic insights," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We're proud to be at the forefront of early cancer detection in dogs and look forward to expanding IDEXX Cancer Dx to cover other cancer types."
The IDEXX Cancer Dx panel features:
- Accuracy: High sensitivity and specificity yield results that can be used with confidence for both sick dogs and in routine preventive care for at-risk dogs.
- Simplicity: Designed to fit existing veterinary workflows, clinicians can add IDEXX Cancer Dx to existing diagnostic wellness panels, using a single blood sample.
- Personalized guidance and comprehensive support: Every IDEXX Cancer Dx result comes with access to IDEXX Medical Consultants, including board-certified oncologists and internists. Pet-owner education materials and resources to support client communications are also provided.
- Actionable next steps: IDEXX Cancer Dx with lymphoma delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be provided with positive results as available at no additional cost.
- Deeper insights: IDEXX Preventive Care, the most comprehensive portfolio of products and services supporting veterinarians with preventive care, will now include IDEXX Cancer Dx testing, unlocking additional insights for at-risk dogs.
"IDEXX Cancer Dx is a powerful innovation in oncology diagnostics," said Timothy Fan, DVM, PhD, DACVIM (Oncology, Small Animal Internal Medicine). "At an affordable price point, this test increases access to cancer diagnoses and care, and it enables veterinarians the opportunity to intervene sooner and improve the quality of life for canine cancer patients."
With IDEXX Cancer Dx testing, general practitioners can now provide a clinical diagnosis of lymphoma earlier than traditional diagnostics.5 Its affordability and ease of integration make it an essential tool for practices committed to proactive cancer management.
IDEXX Cancer Dx with canine lymphoma will be available at the IDEXX Reference Laboratories in the
About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to
*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.
†Veterinarians in
References
- Data on file at IDEXX Laboratories, Inc.
Westbrook, Maine USA: Number of 2023 medicalized dogs who are at-risk breeds ≥ 4 years or senior dogs (≥ 7 years) based on IDEXX Practice Intelligence Data. - What are the most common types of cancers in dogs? How many dogs typically get cancer? Veterinary Cancer Society; 2021. Accessed January 16, 2024. www.vetcancersociety.org/pet-owners/faqs
- Vail DM, Pinkerton M, Young KM. Hematopoietic tumors. In: Vail DM, Thamm DH, Liptak JM, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Saunders; 2020:688–772. doi:10.1016/B978-0-323-59496-7.00033-5
- Data on file at IDEXX Laboratories, Inc.
Westbrook, Maine USA: IDEXX quantitative research with dog owners, May 2024 (n = 480). - Data on file at IDEXX Laboratories, Inc.
Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories inNorth America between November 1, 2024, and December 6, 2024. Analysis Report: IDEXX Cancer Dx Validation, 100282 [008_CancerDx-Validation-Report-2.Rmd].
View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-announces-groundbreaking-cancer-dx-panel-with-affordable-early-detection-test-for-canine-lymphoma-302356451.html
SOURCE IDEXX Laboratories, Inc.
FAQ
When will IDEXX Cancer Dx (IDXX) be available in the US and Canada?
How much does the IDEXX Cancer Dx lymphoma test cost?
What is the turnaround time for IDEXX Cancer Dx test results?
What percentage of new canine cancer diagnoses are lymphoma?
How many dogs are at higher risk for cancer in North America?
What additional features are included with positive IDEXX Cancer Dx results?
